JPRN-jRCT2080222714已完成1 期
A phase Ib dose escalation study of the combination of ribociclib with letrozole and dose expansion of ribiciclib with hormonal therapy for the treatment of pre-(with goserelin) and postmenopausal women with hormone receptor positive HER2-negative, advanced breast cancer
ovartis Pharma. K.K.0 个研究点目标入组 60 人开始时间: 2015年1月8日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •Women with advanced breast cancer not amenable to curative therapy.
- •-HR positive, HER2 negative.
- •-Patient has an Eastern Cooperative Oncology Group (ECOG) performance status (PS)
- •of 0 or 1.
- •-Patient has adequate bone marrow and organ function.
排除标准
- •-Patients with inflammatory breast cancer.
- •-Patient who received any prior systemic anti-cancer therapy for advanced breast cancer.
- •-Patient is currently using other anti-cancer therapy.
- •-Patient has a concurrent malignancy.
- •-Patient has clinically significant, uncontrolled heart disease and/or cardiac repolarization
- •abnormality.
研究者
相似试验
终止
1 期
A phase Ib study of oglufanide disodium (IM862) in patients with chronic HCV infectioChronic Hepatitis CInflammatory and Immune System - Other inflammatory or immune system disordersACTRN12606000505505Implicit Bioscience Pty Ltd32
尚未招募
1 期
A phase 1a/b dose-escalation and dose-expansion study to evaluate Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising Capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC)metastatic castration-resistant prostate cancerCancer - ProstateACTRN12623001072606South Metropolitan Health Service (SMHS)45
招募中
1 期
Tucatinib plus trastuzumab and oxaliplatin-based chemotherapy or pembrolizumab-containing combinations for HER2+ gastrointestinal cancersColorectal adenocarcinoma (CRC), Gastric adenocarcinoma, GEJ adenocarcinoma,JPRN-jRCT2031220143Mayor JoAl40
进行中（未招募）
1 期
Phase 1b dose escalation and dose expansion study in patients with advanced or metastatic non-small cell lung cancer (NSCLC)Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with mutations in a gene called epidermal growth factor receptor (EGFR) or human epidermal growth factor receptor 2 (HER2).NSCLC harboring activating EGFR or HER2 kinase domain mutationsCancerISRCTN99682126Syneos Health UK Limited108
尚未招募
1 期
GO42144CancerPACTR202203779032822Genentech Inc.10